ArticleSexually transmitted infections2026
Acceptability and use of doxyPEP among cisgender men who have sex with men, transgender women and non-binary persons assigned male sex at birth: results from a national online survey from the USA.
Article in Sexually transmitted infections, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundSexually transmitted infections (STIs) have continued to rise in the USA, and doxycycline postexposure prophylaxis (doxyPEP) has shown prevention efficacy for bacterial STIs. We sought to evaluate doxyPEP interest, use and its associated factors among a national sample of eligible users.
methodsUsing national advertisements on a social networking application for men who have sex with men (MSM), we recruited participants to complete an anonymous cross-sectional online survey from 1 March to 30 April 2023. Analyses of doxyPEP user characteristics and factors associated with use were restricted to respondents assigned male sex at birth, residing in the USA and eligible for doxyPEP. Eligibility was defined as self-report of a bacterial STI in the past year following the US Centers for Disease Control and Prevention guidelines. A multivariate logistic regression model was used to evaluate the factors associated with doxyPEP use.
resultsOf 1428 respondents, only 9% reported ever using doxyPEP and 2.5% reported current use. Most respondents (88.3%) not currently on doxyPEP were interested in using it. Among the 471 eligible respondents included in the analysis, the median age was 37 years; the majority (93.6%) identified as cisgender MSM, 2.5% as transgender and 3.8% as non-binary. Most respondents were from the Southern United States (29.5%) and Western United States (37.6%). Among the eligible participants, 17.0% ever used doxyPEP. The majority received doxyPEP from their healthcare provider or STI clinic. Self-identifying as black race (adjusted OR (aOR) 3.08, 95% CI 1.31 to 7.16), reporting a higher number of sex partners (aOR 1.02, 95% CI 1.01 to 1.03), current pre-exposure prophylaxis use (aOR 3.61, 95% CI 1.55 to 9.74) and living with HIV (aOR 3.08, 95% CI 1.20 to 8.83) were associated with doxyPEP use in a multivariable model.
conclusionA national online survey among cisgender MSM, transgender and non-binary persons showed high interest but low use of doxyPEP, which was expected as there were no national guidelines in place at the time. These findings provide baseline estimates to inform future monitoring of doxyPEP uptake.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.